Clinical trial registry record

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 24, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05170828
Last registry update
February 24, 2026
Status
Withdrawn
Phase
Phase 1
Sponsor
Ossium Health, Inc.
Enrollment
0
Match confidence
90%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 18 Years to 70 Years
Duration
2022-09-01 to 2024-11-01
Intervention
Cyclophosphamide; Fludarabine; Total Body Irradiation; Busulfan; Mesna; Sirolimus; Mycophenolate Mofetil; Filgrastim; Bone Marrow Transplant
Comparator
Not reported
Outcomes measured
Neutrophil engraftment — Day 35 Post HCT; Cumulative incidence and kinetics of neutrophil and platelet recovery — Day 35 Post HCT; Overall survival (OS) — 1-year Post HCT; Cumulative incidences of aGVHD and cGVHD — 1-year Post HCT; Transplant-related mortality (TRM) — Day 100 and 1-year Post HCT; NK, B- and T-cell immune reconstitution — Days 35, 100, 180, and 1-year Post HCT; Progression free survival (PFS) — 1-year Post HCT; Event free survival (EFS) — 1-year Post HCT; GVHD relapse free survival (GRFS) — 1-year Post HCT; Cumulative incidence of cytokine release syndrome (CRS) — Day 14 Post HCT; Donor chimerism — Days 35, 56, 100, 180, and 1-year Post HCT; Cumulative incidences of viral reactivations and infections — Days 100, 180, and 1-year Post HCT; Cumulative incidence of primary disease relapse/progression — 1-year Post HCT
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 90% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 90%Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON